Mangoceuticals, Inc. (NASDAQ: MGRX) shares were flat Tuesday. The Dallas-based company focused on developing, marketing, and selling a variety of men’s health and wellness products in the areas of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited to announce obtaining Drug Enforcement Agency (DEA) authorization for the company’s groundbreaking HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the forefront of the direct-to-consumer (DTC) telemedicine market.
Securing DEA clearance to prescribe controlled medications via Surescripts, the nation’s leading health information network, sets MangoRx apart from its competitors, validating its cutting-edge technology and regulatory compliance. This approval aims to give MangoRx’s provider network more flexibility in prescribing custom medication and treatments to include a comprehensive range of controlled substances such as hormone replacement therapies – which they anticipate will drive significant growth in this category. The DEA approval provides a robust foundation for the company’s future expansion and success, ensuring adherence to stringent regulatory standards while fostering innovation.
COO Amanda Hammer highlights the system’s transformative impact and the significance of the DEA approval: “This authorization through Surescripts marks a pivotal moment for MangoRx. Our system is now capable of supporting hyper growth and has the limitless ability to add new and innovative products.”
MGRX shares were down less than a cent to 38 cents.
